GlassScriptPhysician profile
Jacob Aaron Urda
NPI 1427445477
$4,760.73
in general payments reported to CMS, 2019-2025
29 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $109 · 2021: $364 · 2022: $891 · 2023: $1,066 · 2024: $1,122 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $847.49 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $820.35 | 2019-2025 | Farxiga, Airsupra, Tezspire |
| Novo Nordisk INC | $778.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $469.20 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $397.11 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.26 | 2021-2025 | Ofev |
| Amgen INC. | $152.54 | 2022-2024 | Otezla, Repatha, Tezspire |
| Genzyme Corporation | $112.31 | 2024 | |
| Philips North America LLC | $101.18 | 2023-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $99.95 | 2021-2025 | Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $87.87 | 2022-2025 | |
| Pfizer INC. | $67.71 | 2021-2024 | |
| Baxter Healthcare | $67.58 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Biosense Webster, INC. | $53.17 | 2025 | Carto 3 |
| Janssen Pharmaceuticals, INC | $49.47 | 2023 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $40.69 | 2025 | |
| Abbott Laboratories | $32.85 | 2022-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $30.49 | 2025 | Zoryve |
| Dexcom, INC. | $26.75 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $25.18 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.46 | 2025 | Gvoke Hypopen |
| Neos Therapeutics, LP | $23.55 | 2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $21.16 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.63 | 2025 | Qelbree |
| United Therapeutics Corporation | $17.83 | 2022 | |
| Sumitomo Pharma America, INC. | $15.77 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $13.52 | 2025 | Contrave |
| Phathom Pharmaceuticals, INC. | $13.23 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Urda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.